NCT01001169View on ClinicalTrials.gov

Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese Children

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 1, 2009

Primary Completion Date

May 17, 2010

Study Completion Date

May 17, 2010

Conditions
Influenza
Interventions
BIOLOGICAL

GSK Biologicals' Pandemic influenza (H1N1) candidate vaccine (GSK2340274A)

Two intramuscular injections

Trial Locations (1)

157-8535

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01001169 - Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese Children | Biotech Hunter | Biotech Hunter